Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-12-11
2010-06-01
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001850, C424S001890, C549S001000, C549S200000, C549S400000
Reexamination Certificate
active
07727511
ABSTRACT:
Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.
REFERENCES:
patent: 4560534 (1985-12-01), Kung et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5272055 (1993-12-01), Haley
patent: 5434050 (1995-07-01), Maggio et al.
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5670634 (1997-09-01), Marotta et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5811310 (1998-09-01), Ghanbari et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 6054114 (2000-04-01), Lansbury, Jr. et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6114175 (2000-09-01), Klunk et al.
patent: 6133259 (2000-10-01), Klunk et al.
patent: 6168776 (2001-01-01), Klunk et al.
patent: 6274119 (2001-08-01), Barrio et al.
patent: 6287793 (2001-09-01), Schenk et al.
patent: 6331440 (2001-12-01), Nordstedt et al.
patent: 6417178 (2002-07-01), Klunk et al.
patent: 6784180 (2004-08-01), He et al.
patent: 7166274 (2007-01-01), Candau
patent: 2002/0159947 (2002-10-01), Zaczek et al.
patent: 2002/0182152 (2002-12-01), Goldstein et al.
patent: WO 89/06242 (1989-07-01), None
patent: WO 93/04194 (1993-03-01), None
patent: WO 97/41856 (1997-11-01), None
patent: WO 98/27972 (1998-07-01), None
patent: WO 01/87354 (2001-11-01), None
Maria M. Piken, “The Changing Concepts of Amyloid”, Arh Pathol Lab Med—vol. 125, Jan. 2001, pp. 8-9, 40-43.
Gary W. Small et al., “In Vivo Brain Imaging of Tangle Burden in Humans”, Jornal of Molecular Neuroscience, vol. 19, 2002, pp. 323-327.
Chester A. Mathis, et al., “A Lipophilic Thioflavin-T Derivative for Positron Emission Tomography (PET) Imaging of Amyloid in Brain”, Biorgaic & Medicinal Chemistry Letters 12, 2002, pp. 295-298.
William E. Klunk et al., “Quantifying Amyloid β-Peptide (Aβ) Aggregation Using the Congo Red-Aβ(CR-AβSpectrophotometric Assay”, Analytical Biochemistry 266,, 1999, pp. 66-76.
Chester Mathis et al., “Imaging Technology for Neurodegenerative Diseases”, Arch. Neurol., vol. 62, 2005, pp. 196-200.
Nobuyuki Okamura et al., “A Novel Imaging Probe for In Vivo Detection of Neuritic and Diffuse Amyloid Plaques in the Brain”, Journal of Molecular Neuroscience, vol. 24, 2004, pp. 247-255.
Margaret Sunde et al., “Common Core Structure of Amyloid Fibrils by Synchrotron X-ray Diffraction”, J. Mol. Biol., 1997, 273, pp. 729-739.
Masahiro Ono et al., “Benzofuran Derivatives as Aβ-aggregate-specific Imaging Agents for Alzheimer's Disease”, Nuclear Medicine and Biology 29, 2002, pp. 633-642.
Justin Legleiter et al., “Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy”, J. Mol. Biol. 2004, 335, pp. 997-1006.
S. Heckl et al., “Molecular Imaging: Bridging the Gap Between Neuroradiology and Neurohistology”, Histol. .Histopathol, 2004, pp. 651-668.
A.R. Oksengaard et al., “Accuracy of CT Scan Measurements of the Medial Temporal Lobe in Routine Dementia Diagnostics”, International Journal of Geriatric Psychiatry, 2003, 18:, pp. 308-312.
Nobuyuki Okamura et al., “Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain”, The Journal of Neuroscience, March 10, 2004, 24(10): pp. 2535-2541.
Dimitra G. Georganopoulou et al., “Nanoparticle-based Detection in Cerebral Spinal Fluid of Soluble Pathogenic Biomarker for Alzheimer's Disease”, PNAS, Feb. 15, 2005, vol. 102, No. 7, pp. 2273-2276.
Alex E. Roher et al., “β-Amyloid-(1-42) is a Major Component of Cerebrovascular Amyloid Deposits: Implications for the Pathology of Alzheimer Disease”, Proc. Natl. Acad. Sci., vol. 90, pp. 10836-10840 (year not provided).
Judianne Davis-Salinas et al., “Amyloid β-Protei n. Aggregation Nullifies Its Pathologic Properties in Cultured Cerebrovascular Smooth Muscle Cells”, The Journal of Giological Chemistry, vol. 270, No. 36, Sep. 8, 1995, pp. 20887-20890.
Alex E. Roher et al., “Morphology and Toxicity of Aβ-(1-42) Dimer Derived From Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease”, The Journal of Biological Chemistry, vol. 271, No. 343, August 23, 1996, pp. 20631-20635.
G.D. Fasman et al., “Solubilization of β-amyloid-(1-42)-peptide: Reversing the β-sheet Conformation Induced by Aluminum with Silicates”, Proc. Natl. Acad. Sci., vol. 92, pp. 369-371, Jan. 1995.
Melvin K. Simmons et al., “A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice”, Mol. Imaging Biol., 2005, pp. 69-77.
Caroline Hillbich et al., “Aggregation and Secondary Structure of Synthetic Amyloid βA4 Peptides of Alzheimer's Disease”, J. Mol. Biol., 1991, 218, pp. 149-163.
Dafang Wu et al., “Drug Targeting of a Peptide Radiopharmaceutical Through the Primate Blood-Brain Barrier in Vivo With a Monoclonal Antibody to the Human Insulin Receptor”, The American Society for Clinical Investigation, vol. 100, No. 7, Oct. 1997, pp. 1804-1812.
Wen-hong Li, et al, “Mechanistic Studies of a Calcium-Dependent MRI Contrast Agent”, Inorganic Chemistry, 2002, 41, pp. 4018-4024.
Jean-Cosme Dodart, et al., “Immunization Reverses Memory Deficits Without Reducing Brain Aβ Burden in Alzheimer'S Disease Model”, Nature Neuroscience, vol. 5, No. 5, May 2002, pp. 452- 457.
Dominic M. Walsh, et al., “Naturally Secreted Oligomers of Amyloid βProtein Potentlyshibit Hippocampal Long-Term Potentiation in vivo”, Nature, Apr. 4, 2002, vol. 416, pp. 535-539.
Ronald B. DeMattos, et al, “Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in A Mouse Model of Alzheimer's Disease”, Science, Mar. 22, 2002, vol. 295, pp. 2264-2267.
Jongmin Kang, et al., “The Amide Derivatives of Chrysamine G Protect Human Astrocyte Cells Against Aβ-Induced Toxicity”, Bulletin of the Korean Chemical Society, Mar. 20, 2002, vol. 23, No. 3, pp. 363-364,.
Nancy A. Dezutter, et al., “99mTc-Mama-Chrysamine G, A Probe for Beta-Amyloid Protein of Alzheimer's Disease”, European Journal of Nuclear Medicine, 1999, vol. 26, No. 11, pp. 1392-1399.
Jongmin Kang, et aL, “The Amide Derivates of Chrysamine G Bind to the β-Amyloid Fibril”, Bull. Korean Chem. Soc., 2001, vol. 22, No. 10, pp. 1065-1066.
Rakes Kayed, et al., “Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis”, Science, Apr. 18, 2003, vol. 300, pp. 486-489.
Ralph Weissleder, et al., “In Vivo Imaging of Tumors With Protease-Activated Near-Infrared Fluorescent Probes”, Nature Biotechnology, Apr. 17, 1999, vol. 17, pp. 375-378.
Angelique Y. Louie, et aL, “In Vivo Visualization of Gene Expression Using Magnetic Resonance Imaging”, Nature Biotechnology, Mar. 2000, vol. 18, pp. 321-325.
Wolf, Christman, Fowler, Lambrecht, “Synthesis of Radiopharmaceuticals and Labeled Compounds Using Short-Lived Isotopes”, Symposium on New Developments in Radiopharmaceuticals and Labeled Compounds, vol. 1, p. 345-381 Copenhagen (1973).
Database Crossfire, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002300651, Database accession No. BRN:169730, abstract & J. Amer. Chem. Soc., vol. 96, 1974, pp. 5495-5508.
Database Crossfire, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002300652, Database accession No. BRN:5510834, abstract & J. Amer. Chem. Soc., vol. 51, No. 25, 1986, pp. 5040-5041.
Database Crossfire, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002300653, Database accession No. BRN:3551523, abstract & Bull. Acad. Sci.., vol. 38, No. 3.2, 1989, pp. 579-580.
Maria M. Pi ken, M.D.,
Agdeppa Eric Dustin
Hehir Cristina Tan
Lam Tun Chiao Hubert
Montalto Michael Christopher
Siclovan Tiberiu Mircea
Gallagher Eileen W.
General Electric Company
Jones D L
LandOfFree
Agents for imaging soluble a-beta does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents for imaging soluble a-beta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents for imaging soluble a-beta will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183678